Multigene panels in prostate cancer risk assessment
Little J, Wilson B, Carter R, Walker K, Santaguida P, Tomiak E, Beyene J, Raina P
Record ID 32012000913
English
Authors' objectives:
The aim of this review is to identify, synthesize, and appraise the literature on the analytic validity, clinical validity, and clinical utility of commercially available single nucleotide polymorphism (SNP) panel tests for assessing the risk of prostate cancer.
Authors' recommendations:
The evidence on currently available SNP panels does not permit meaningful assessment of analytic validity. The limited evidence on clinical validity is insufficient to conclude that the panels assessed would perform adequately as screening or risk stratification tests. No evidence is available on the clinical utility of current panels.
Details
Project Status:
Completed
Year Published:
2012
URL for published report:
http://www.ncbi.nlm.nih.gov/books/NBK99070/pdf/TOC.pdf
URL for additional information:
http://www.ahrq.gov/clinic/tp/mgenprcatp.htm
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Humans
- Prostatic Neoplasms
- Risk Factors
- Polymorphism, Genetic
Contact
Organisation Name:
Agency for Healthcare Research and Quality
Contact Address:
Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA. Tel: +1 301 427 1610; Fax: +1 301 427 1639;
Contact Name:
martin.erlichman@ahrq.hhs.gov
Contact Email:
martin.erlichman@ahrq.hhs.gov
Copyright:
Agency for Healthcare Research and Quality (AHRQ)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.